Biotech News

Charles River Laboratories Announces Third-Quarter 2026 Results

Charles River (CRL)Charles RiverEarnings

WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 4, 2026-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter ended September 26, 2026. Key Highlights Reports third-quarter revenue of $982.7 million, GAAP earnings per share of $6.86, and non-GAAP

Related news

Charles River

Preclinical Research Services Charles River Laboratories provides products and outsourced services used by pharmaceutical, biotechnology, academic and government researchers across early drug development. Research Models and Services The company supplies research models and related services used in basic research, target validation and...

Recent company news

Stock data

Close
327.93 USD
Market cap
8.42B USD
Exchange
NYSE
Sector
Biopharma
Location
United States